One of the reasons for GSK not marketing Relenza: GSK does not want Biota to have enough funds for its HRV and Lani programs. These programs, if successful, pose great threads to GSK's Asthmatic drug and flu vaccine sales.
In Phase IIB trials for Vapendavir, it showed that Vapendavir helped patients reduce their use of asthma reliever medication. The magnitude of the reduction is about 50%.
Lani is a currenly the most convenient and effective (no resistance issue so fat) flu drug. So, if it is widely known to and accepted by people, fewer people will be scared by flu vaccine producers' scaring flu advertisements.
Just my opinions.
One of the reasons for GSK not marketing Relenza: GSK does not...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)